MI-CP151 was a phase 1b randomised, double-blind, placebo managed, dose-escalation, multicentre review to evaluate numerous intravenous doses of sifalimumab, in Grownup people with dermatomyositis or polymyositis (NCT00533091). Key trial targets ended up to evaluate the security and tolerability of sifalimumab in dermatomyositis or polymyositis suf